Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide TO 
THE EDITOR
Recently, arsenic trioxide (As 2 O 3 ) was found to be very effective in refractory or relapsed acute promyelocytic leukemia (APL). 1, 2 It acts by triggering apoptosis with only minor effects on differentiation of APL blasts. 2, 3 Remission can be achieved in a large portion of patients without significant bone marrow suppression. Acute side-effects of As 2 O 3 include fluid retention, gastrointestinal and dermatologic symptoms as well as cardiac and hepatic toxicity. After prolonged administration of the drug, chronic side-effects such as polyneuropathy and muscular atrophy have been observed. 1, 4 A 21-year-old woman was diagnosed as suffering from APL in April 1998, based on M3v morphology showing hypogranular blasts with bilobulated nuclei, CD33
+ CD34 + HLA-DR − immunophenotype and cytogenetic evidence of t(15;17). Complete remission was achieved after treatment with all-trans retinoic acid (ATRA) and a course of idarubicin and cytarabine within 4 weeks. After three courses of consolidation chemotherapy treatment was finished in October 1998. In November 1998 multiple palpable reddish skin nodules (diameter 5-10 mm) appeared on the chest and head. A skin biopsy performed at two different sites showed a dermal infiltration by myeloperoxidasepositive leukemic blast cells. Molecular analysis by reverse transcriptase polymerase chain reaction revealed the presence of the PML/RAR␣ fusion gene in the skin lesions and also in the peripheral blood. Morphological examination of peripheral blood and bone marrow showed no signs of relapse at that time. Treatment with ATRA led to a partial regression of the dermal manifestations of APL. In January 1999 after development of thrombocytopenia a medullary relapse was diagnosed despite continuous administration of ATRA. After discontinuation of ATRA a further course of idarubicin and cytarabine was applied. Due to progression of marrow infiltration and disseminated intravascular coagulation (DIC) intravenous treatment with As 2 O 3 (10 mg daily) was initiated in February 1999 after informed consent was obtained. Apart from intermittent abdominal discomfort
Figure 1
Blood counts for white blood cells (WBC ----) and platelets (PLT---), and levels of fibrinogen split products (FSP---) under treatment with As 2 O 3 ( ).
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Leukemia and mild elevation of serum alkaline phosphatase there were no acute side-effects of As 2 O 3 treatment. Following an initial leukocytosis (up to 48.9 g/l) peripheral blood counts and DIC gradually improved ( Figure 1 ). On day 25 of As 2 O 3 therapy the patient complained of headache, diplopia and blurred vision. Electrophysiological examination showed signs of discrete sensory polyneuropathy. There was bilateral papilledema (Figure 2 ) but cranial magnetic resonance imaging revealed no pathological findings except mild distension of the perioptic subarachnoidal space. Due to these signs of elevated intracranial pressure without further pathology a diagnosis of pseudotumor cerebri (PTC) was made. 5 A lumbar puncture was omitted because of
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Fundus oculi showing bilateral papilledema after 25 days of treatment with As 2 O 3 .
severe thrombopenia at that time. After discontinuation of As 2 O 3 the clinical signs of pseudotumor cerebri diappeared within 3 weeks. A bone marrow examination performed at the end of March 1999 (13 days after discontinuation of As 2 O 3 ) showed a complete remission of APL. The skin nodules had also regressed and could only be recognized as faint hyperpigmentations. Examination of the spinal fluid at that time showed no pathological result. The patient remained off therapy and recovered completely until May 1999, when there was still no evidence for relapse. The patient then successfully underwent HLA-identical allogeneic bone marrow transplantation.
Because of limited experience with As 2 O 3 treatment the spectrum of acute and chronic side-effects still remains to be completely defined. 4 The most frequent acute adverse effects of treatment of APL with As 2 O 3 reported so far seem to be fluid retention, cardiac and hepatic toxicity as well as gastrointestinal and dermatological symptoms. Polyneuropathy and muscular atrophy were noted as chronic side-effects. 1, 4 PTC is defined as a clinical pattern characterized by a syndrome of intracranial hypertension without signs of an intracranial spaceoccupying lesion or of an infectious process. 5 Our patient complained about abdominal discomfort during the first days of treatment and a mild elevation of alkaline phosphatase was noted. There was no further evidence of acute As 2 O 3 toxicity until the symptoms of elevated intracranial pressure occurred.
Several cases of PTC after differentiation therapy with ATRA for APL have been described in the literature, especially occurring in pediatric patients and associated with hyperleukocytosis. Vasogenic cerebral edema induced by the disruption of the integrity of the blood-brain barrier may possibly account for the iatrogenic type of PTC. 5 A further possible mechanism might be increased production of cerebrospinal fluid through disturbance of the Na+/K+ adenosine triphosphatase pump or modulation of the intracellular levels of cyclic adenosine monophosphate in the arachnoid villi. The exact pathogenesis, however, still remains to be established. After drug withdrawal the symptoms usually regress rapidly. [6] [7] [8] Our patient is an adult and occurrence of PTC was not associated with leukocytosis. Since there were no signs of any central nervous system abnormality and symptoms regressed upon drug withdrawal, it seems likely that PTC was caused by As 2 O 3 . ATRA was given to our patient twice previously for an overall duration of about 6 months, and during those periods there occurred no neurological symptoms.
To our knowledge, this is the first report of a case of PTC associated with treatment of APL with As 2 O 3 . Although PTC is a rare complication in adult APL, it is important to differentiate it from cerebral hemorrhage and one has to be aware that PTC may not only occur after differentiation therapy with ATRA but also after salvage treatment with As 2 O 3 .
Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele TO 
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The myelodysplastic syndromes (MDS) are clonal disorders originating from a pluripotent stem cell. Cytopenia is frequently observed in such patients. Because of the similarities between aplastic anemia (AA) and hypoplastic MDS, immunosuppressive therapies such as high-dose methylprednisolone, antithymocyte globulin (ATG), and 
